Citi Boosts Eli Lilly with Buy Rating, Eyes Growth
Citi resumes Eli Lilly coverage with Buy rating, driven by optimistic tirzepatide forecasts for diabetes and obesity treatments.
- Latest
- Trending
Citi resumes Eli Lilly coverage with Buy rating, driven by optimistic tirzepatide forecasts for diabetes and obesity treatments.
"ResMed and Inspire Medical stocks plummet after Eli Lilly's Zepbound trial success; Citi downgrades RMD, sees market shift. Read more ...
Eli Lilly's Zepbound reduces sleep apnea by up to 52% in trials, showing promise beyond weight loss. FDA approval for ...
Pfizer's interest in the weight loss market is uncertain due to its significant debt of over $70 billion and recent ...
Discover the promising future for investors in Eli Lilly and Company (NYSE: LLY), a leader in the biopharmaceutical industry, with ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.